Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$33.5 million.

  • Inhibrx Biosciences' Net Cash Flow fell 9.67% to -$33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 69.33%. This contributed to the annual value of -$125.3 million for FY2024, which is 3187.66% down from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Net Cash Flow is -$33.5 million, which was down 11.77% from -$30.0 million recorded in Q2 2025.
  • Inhibrx Biosciences' Net Cash Flow's 5-year high stood at $144.8 million during Q3 2023, with a 5-year trough of -$59.4 million in Q4 2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$30.0 million (2025), whereas its average is -$4.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 121.08% in 2024, then spiked by 351.26% in 2025.
  • Inhibrx Biosciences' Net Cash Flow (Quarterly) stood at -$59.4 million in 2023, then increased by 26.37% to -$43.7 million in 2024, then declined by 9.67% to -$33.5 million in 2025.
  • Its Net Cash Flow was -$33.5 million in Q3 2025, compared to -$30.0 million in Q2 2025 and $63.9 million in Q1 2025.